Showing results (2701-2710 of 5,702) with videos related to

Sort By:
Pageof 571
The Oncologist|May 21, 2026
Patient-reported time toxicity with bispecific antibody therapies in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphomaAjay Major, Esprit Ma, Anthony Masaquel, et al.
The Oncologist|May 24, 2026
The 7th Kidney Cancer Research Summit: Progress in Accelerating CuresToni K Choueiri, A Ari Hakimi, Rana McKay, et al.
The Oncologist|May 25, 2026
Real-World outcomes and prognostic factors in anaplastic thyroid cancer: Evidence from the REGETNE-Thyroid cohortPau Mascaró-Baselga, José Miguel Rodellar Sanz, Tiago Nunes, et al.
The Oncologist|May 4, 2026
Cost, Context, and Confounding: Rethinking Real-World data Generation and Interpretation in Advanced NSCLCMehmet Mutlu Çatlı, Arif Hakan Önder
The Oncologist|March 16, 2026
Comparison of Six Cycles with Four Cycles of Chemotherapy and Atezolizumab in the First-Line Treatment of ES-SCLC; A Retrospective Multicenter AnalysisHalil Göksel Güzel, Derya Kıvrak Salim, Saadettin Kılıçkap, et al.
The Oncologist|March 16, 2026
Planned Time Burden for Patients Participating in Phase 2 Cancer TrialsCharlotte Ouimet, Renata Iskander, Ryan Nipp, et al.
The Oncologist|March 18, 2026
Phase 2 Study of Azacitidine plus Pembrolizumab as Second-Line Treatment in Patients with Locally Advanced or Metastatic Pancreatic Ductal AdenocarcinomaRachael A Safyan, Ruth A White, Tamas A Gonda, et al.
The Oncologist|March 14, 2026
Anti-EGFR plus anti-PD1 in advanced and refractory cutaneous squamous cell carcinoma: a cohort studyCamille Guy, Candice Hober, Sophie Maiezza, et al.
The Oncologist|March 14, 2026
Telemedicine as a Gateway to Early-Phase Oncology Trials: Lessons from 14,000 Patients and Future Directions for Global Access and EquityCarlos Torrado, Clark R Andersen, Lei Kang, et al.
The Oncologist|February 25, 2026
Prognostic significance of preoperative thyroid hormone sensitivity status for recurrence in papillary thyroid carcinomaCanxiao Li, Shijie Li, Yishen Zhao, et al.
Pageof 571